Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

NCT05848440 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05848440
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05848440 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
May 2, 2023
Completion date
November 13, 2023
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis